08:10 AM EDT, 10/23/2026 (MT Newswires) -- Novartis' (NOVN.SW) Kisqali, or ribociclib, plus endocrine therapy showed "positive, clinically meaningful" overall survival in the six-year follow-up analysis of its phase 3 Natalee trial. The trial, which compared the combination treatment with endocrine therapy alone, showed that the former reduced the risk of death by 19.1%, with a consistent overall survival benefit across all key subgroups, according to a Friday release. The trial enrolled the broadest early breast cancer population of patients with stage 2 and 3 HR+/HER2- early breast cancer at high risk of recurrence, including those with high-risk node-negative disease and all node-positive patients. With the longer follow-up, the safety profile of the drug combo remained consistent with earlier analyses, and no new safety signals were reported.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.